Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 4/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.35 |
| ▸ | SELL | P14151 | 6/20 | 0.32 |
| ▸ | SELP | P16109 | 6/20 | 0.32 |
| ▸ | CA1 | P00915 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20161919 | 0.82 | SMN1; SMN2 (0.36) | SMN1; SMN2CA2CA9CA12FUCA1 | |
| SCHEMBL20161901 | 0.79 | CA9 (0.34) | SMN1; SMN2CA2CA9CA12FUCA1 | |
| SCHEMBL20161694 | 0.79 | FUCA1 (0.37) | CA2CA9CA12FUCA1 | |
| SCHEMBL20161561 | 0.78 | PYGB (0.43) | CA2CA9CA12CA1 | |
| SCHEMBL20161908 | 0.78 | PYGB (0.43) | CA2CA9CA12CA1 | |
| SCHEMBL20161563 | 0.78 | PYGB (0.43) | CA2CA9CA12CA1 | |
| SCHEMBL20161420 | 0.75 | MMP8 (0.42) | — | |
| SCHEMBL20161683 | 0.75 | MMP8 (0.42) | — | |
| SCHEMBL20161308 | 0.74 | FUCA1 (0.31) | CA2CA9CA12FUCA1SELP | |
| SCHEMBL30590234 | 0.73 | FUCA1 (0.42) | SMN1; SMN2CA2CA9CA12FUCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11045411-B2 | Process for treating keratin materials using amide, acid or ester c-glycoside derivatives, and cosmetic composition containing same | L'OREAL (FR) | 2021-06-29 | — | — | US | disclosed |
| US-20180133137-A1 | PROCESS FOR TREATING KERATIN MATERIALS USING AMIDE, ACID OR ESTER C-GLYCOSIDE DERIVATIVES, AND COSMETIC COMPOSITION CONTAINING SAME | L'OREAL (FR) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180133137-A1 | PROCESS FOR TREATING KERATIN MATERIALS USING AMIDE, ACID OR ESTER C-GLYCOSIDE DERIVATIVES, AND COSMETIC COMPOSITION CONTAINING SAME | KRT18, CUTA, GLA | SMN1; SMN2 4796/4885CA2 1939/4885CA9 451/4885 |
| US-11045411-B2 | Process for treating keratin materials using amide, acid or ester c-glycoside derivatives, and cosmetic composition containing same | KRT18, CUTA, GLA | SMN1; SMN2 4796/4885CA2 1939/4885CA9 451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.